At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 295 enrolled
Drug / intervention
TD-9855 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Proof-of-Concept Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
In Brief
A Phase 2 clinical trial evaluating TD-9855 and Placebo for Attention-Deficit/Hyperactivity Disorder and ADHD. Completed, enrolled 295 participants across 17 sites.
Detailed Summary
The safety and efficacy of multiple dosages of TD-9855, administered once daily, will be evaluated in adult males with ADHD.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAttention-Deficit/Hyperactivity Disorder, ADHD
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedOct 2011
Enrollment StartDec 2011
Primary CompletionOct 2013
Study CompletionNov 2013
TodayJul 2026
First PostedOct 24, 2011
Enrollment StartDec 1, 2011
Primary CompletionOct 1, 2013
Study CompletionNov 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 14.7 years ago
Interventions
TD-9855drug
Once daily
TD-9855drug
Once daily
Placebodrug
Once daily